Kimryn Rathmell MD PhD MMHC the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center will be appointed Director of the National Cancer Institute.

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

Vanderbilts James E. Crowe Jr MD and Neil Osheroff PhD are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event.

Nancy Cox PhD director of the Vanderbilt Genetics Institute is the recipient of the 2023 ASHG Leadership Award from the American Society of Human Genetics.

An international coalition of biomedical researchers co-led by Vanderbilts Alexander Bick MD PhD has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients risk of blood cancer.

Understanding the dynamic regulation of cytoskeletal microtubules may suggest new ways to treat disorders ranging from Alzheimer's disease to cancer.

Jason MacGurn and colleagues have characterized a “rheostat” that sets WNT pathway signaling in breast cancer cells.

Vanderbilt University researchers have discovered how a protein pump distinguishes between chemicals that it will expel from a cell and inhibitors that block its action - findings that could guide the development of more efficient inhibitors to prevent cancer cell resistance to chemotherapy.

A recent study suggests that blocking the MYC protein could be “unexpectedly effective” in treating malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers.

The 20th Annual Scientific Retreat will be held Wednesday, May 1, 8:30 a.m.

Finding gives boost to fighting cancer through cell metabolism

Uncontrolled activation of RAS causes approximately a third of all tumors and helps cancerous cells evade anti-cancer drugs. Vanderbilt researchers have identified small molecules that target this pathway and further defined how these small molecule compounds work.

Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.

Carlos F. Lopez, PhD, and colleagues propose a new “conveyor belt” mechanism for how cellular signaling is amplified, or strengthened, as signals are handed off from one enzyme to the next.

Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)

Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.